Compugen doses first patient in ovarian cancer combination study

Compugen announced that the first patient has been dosed in the triple immunotherapy combination proof-of-concept study evaluating COM701, Compugen’s potential first-in-class anti-PVRIG antibody, with COM902, Compugen’s potential anti-TIGIT antibody and pembrolizumab in patients with platinum resistant ovarian cancer. This proof-of-concept study is an open label study evaluating the combination of COM701 with COM902 and pembrolizumab in up to 40 patients with high grade platinum resistant epithelial ovarian cancer including patients with fallopian tube cancer and primary peritoneal cancer who have received up to 3 lines of prior therapy for platinum resistant ovarian cancer. The initiation of the study is based on Phase 1 cohort expansion data reported at ESMO-IO 2022, showing a favorable safety and tolerability profile and durable anti-tumor activity with the combination of COM701 and nivolumab +/- BMS-986207 in platinum resistant ovarian cancer patients.